Company news
Telix Pharmaceuticals Limited (ASX:TLX) news
Telix Pharmaceuticals Limited news releases on 6ix. Latest, Aug 15, 2022: Grand Pharmaceutical Groups investment in Telix
Press releases — page 5
Grand Pharmaceutical Groups investment in Telix
August 14, 2022
APAC Regulatory Progress Prostate and Kidney Cancer Imaging
August 1, 2022
Appendix 4C and Activities Report for June 2022 Quarter
July 20, 2022
Kevin Richardson appointed as CEO, Telix Americas
July 10, 2022
Distribution Agreement with Isologic for Illuccix in Canada
June 22, 2022
Expansion of Partnership with RefleXion for Prostate Cancer
June 9, 2022
Telix receives AUD$17.25 million R&D tax refund
June 6, 2022
Leadership changes including Darren Smith appointment as CFO
May 31, 2022
Illuccix Reimbursement Milestone and Launch Updates
May 29, 2022
Appendix 4C and Activities Report for March 2022 quarter
April 21, 2022
ProstACT TARGET Phase II Study Ethics Approval
April 11, 2022
Telix Enters Licence Agreement with Lilly for Olaratumab
April 10, 2022
Telix, GMS & Monash Awarded $23 million Federal Funding
April 4, 2022
Commercial Launch - Illuccix Now Available to Order in US
April 3, 2022
FDA Orphan Drug Designation for Bone Marrow Conditioning
March 29, 2022
Telix and Xiel Sign U.K. and Ireland Distribution Agreement
March 28, 2022
Development of Glioblastoma Therapy Program
March 22, 2022
Radiopharmaceutical Production Facility Buildout Commences
March 21, 2022
ZIRCON Phase 3 Imaging Study Completes Targets Enrolment
March 7, 2022
Cancellation of Share Purchase Plan
March 1, 2022
2021 Full Year Results Presentation
February 23, 2022
Commercial Distribution Agreement for Illuccix for Australia
February 15, 2022
Telix Granted Illuccix EU Regulatory Review Extension
February 6, 2022
Sydney Airport to be removed from the S&P/ASX 200 Index
February 3, 2022
1st Patient Dosed ProstACT Prostate Cancer Therapy Program
January 26, 2022
Appendix 4C and Activities Report for December 2021 Quarter
January 23, 2022
Targeted Alpha Therapy for Bladder Cancer 1st patient dosed
December 20, 2021
FDA Approves Telix Prostate Cancer Imaging Product Illuccix
December 19, 2021
Illuccix EU Regulatory Submission Progress Update
December 9, 2021
NUCLIBER - Distribution Agreement for Illuccix in Spain
December 7, 2021
Illuccix Granted Use Authorisation in Brazil
November 30, 2021
Investor Presentation - November 2021
November 15, 2021
Australian TGA Approves Illuccix for Prostate Cancer Imaging
November 1, 2021
Activities Report and App 4C - September 2021 quarter
October 20, 2021
IPAX-1 Presentation at Congress of Neurological Surgeons
October 19, 2021
$12.1M R&D Tax Refund, Overseas Finding Increased to $139M
September 27, 2021
FDA Extends New Drug Application Review Period for Illuccix
September 22, 2021
FDA Approves Phase II Kidney Cancer Therapy Study
September 13, 2021
Telix and Radius sign Distribution Agreement for Italy
September 12, 2021
Results Presentation and Shareholder Update 1H 2021
August 18, 2021
Telix and Merck pan-cancer clinical collaboration
August 17, 2021
TLX66 in Phase II Academic Study of Pediatric Leukemia
August 16, 2021
Telix Seneffe Production Facility - Progress Update
July 29, 2021
App 4C and Activities Report for June 2021 Quarter
July 21, 2021
ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
July 19, 2021
TLX101 for Glioblastoma Therapy - Clinical Trial Update
June 20, 2021
Update on FDA New Drug Application Review for Illuccix
June 16, 2021
US Co-Promotion with EZAG for Prostate Cancer Imaging
June 3, 2021
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
May 24, 2021
German Distribution Agreement with Eckert and Ziegler
May 17, 2021